Vestronidase alfa

From WikiProjectMed
Jump to navigation Jump to search

Vestronidase alfa
File:Mepsevii-Vial-Front-PDP-1.png
Names
Trade namesMepsevii
Other namesVestronidase alfa-vjbk
Clinical data
Drug classEnzyme[1]
Main usesMucopolysaccharidosis type VII (Sly syndrome)[2]
Side effectsDiarrhea, rash, anaphylaxis[1][2]
Routes of
use
Injection
Typical dose4 mg/kg[2]
External links
AHFS/Drugs.comMonograph
US NLMVestronidase alfa
Legal
License data
Legal status
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Chemical and physical data
FormulaC3308H4996N874O940S16
Molar mass72562.49 g·mol−1

Vestronidase alfa, sold under brand name Mepsevii, is a medication used to treat mucopolysaccharidosis type VII (Sly syndrome).[2] It is given by injection into a vein over four hours.[2]

Common side effects include swelling at the site of injection, diarrhea, rash, and anaphylaxis.[1][2] It is a recombinant form of the human enzyme beta-glucuronidase; and works by replacing this missing enzyme.[2][1]

Vestronidase alfa was approved in the United States in 2017 and Europe in 2018.[1][2] In the United States it costs about 2,400 USD for 10 mg as of 2021 or about 624,000 USD a year for someone who weights 25 kg.[3]

Medical uses

Mepsevii is indicated for the treatment of non-neurological manifestations of mucopolysaccharidosis VII (MPS VII; Sly syndrome).[2][4]

Dosage

The typical dose is 4 mg/kg every two weeks.[2]

History

The safety and efficacy of vestronidase alfa were established in a clinical trial and expanded access protocols enrolling a total of 23 participants ranging from five months to 25 years of age.[5] Participants received treatment with vestronidase alfa at doses up to 4 mg/kg once every two weeks for up to 164 weeks.[5] Efficacy was primarily assessed via the six-minute walk test in ten participants who could perform the test.[5] After 24 weeks of treatment, the mean difference in distance walked relative to placebo was 18 meters.[5] Additional follow-up for up to 120 weeks suggested continued improvement in three participants and stabilization in the others.[5] Two participants in the vestronidase alfa development program experienced marked improvement in pulmonary function.[5] Overall, the results observed would not have been anticipated in the absence of treatment.[5] The effect of vestronidase alfa on the central nervous system manifestations of MPS VII has not been determined.[5]

The FDA approved vestronidase alfa-vjbk based primarily on evidence from one clinical trial (NCT02230566) of 12 participants with mucopolysaccharidosis VII. The trial was conducted at four sites in the United States.[6] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

The benefit and side effects of vestronidase alfa were based primarily on one trial.[6] Participants were randomly assigned to four groups.[6] Three groups of participants received placebo treatment before starting vestronidase alfa treatment and one group received vestronidase alfa only.[6] vestronidase alfa or placebo were given once every two weeks as intravenous (IV) infusions.[6] Neither participants nor healthcare providers knew which treatment was given until after the trial was competed.[6]

The benefit of 24 weeks of vestronidase alfa treatment was primarily evaluated by the 6-minute walking test (6MWT) and compared to placebo treatment in ten participants who could perform the test.[6] The 6MWT measured the distance a patient could walk on a flat surface in 6 minutes.[6] An additional follow-up using 6MWT was done for up to 120 weeks.[6]

The application for vestronidase alfa was granted fast track designation, orphan drug designation, and a rare pediatric disease priority review voucher.[5] This was the twelfth rare pediatric disease priority review voucher issued.[5]

The U.S. Food and Drug Administration (FDA) granted approval of Mepsevii to Ultragenyx Pharmaceutical, Inc,[5] and required the manufacturer to conduct a post-marketing study to evaluate the long-term safety of the product.[5]

References

  1. 1.0 1.1 1.2 1.3 1.4 "Vestronidase Alfa-vjbk Monograph for Professionals". Drugs.com. Retrieved 13 September 2021.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 "Mepsevii EPAR". European Medicines Agency (EMA). Retrieved 28 February 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. "Mepsevii Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 13 September 2021.
  4. "Mepsevii- vestronidase alfa injection". DailyMed. 19 November 2017. Retrieved 5 August 2020.
  5. 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 "FDA approves treatment for rare genetic enzyme disorder" (Press release). U.S. Food and Drug Administration (FDA). 15 November 2017. Archived from the original on 10 December 2019. Retrieved 9 December 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  6. 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 "Drug Trial Snapshot: Mepsevii". U.S. Food and Drug Administration (FDA). 4 December 2017. Archived from the original on 10 December 2019. Retrieved 9 December 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  7. New Drug Therapy Approvals 2017 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2018. Retrieved 16 September 2020.

External links

Identifiers:
  • "Vestronidase alfa". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT02230566 for "A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)" at ClinicalTrials.gov